A new treatment for systemic lupus erythematosus (SLE) could significantly reduce disease activity, results show. 

Johnson & Johnson, which developed nipocalimab, says it is the first neonatal Fc receptor (FcRn) blocker to be studied in systemic lupus erythematosus. The blocker is designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies associated with this disease while preserving immune function. 

By reducing circulating IgG, including autoantibodies, nipocalimab is designed to target the underlying cause of disease while preserving critical immune functions. 

In the Phase II JASMINE study, nipocalimab decreased disease activity at the primary endpoint of 24 weeks, subsequently reducing activity through to 52 weeks, as measured by both SRI-4 and LLDAS. 

The study results also showed greater response versus placebo plus background medication in participants who tested positive for lupus-associated autoantibodies, which represents approximately 80% of people living with SLE. 

“Findings from the JASMINE study mark an important step in advancing research in systemic lupus erythematosus, a complex autoantibody disease that can have profound impact on daily life for people living with moderate to severe disease,” said Mark Graham, Therapeutic Area Head, Immunology, Europe, Middle East and Africa at Johnson & Johnson.  

“These results reflect our commitment to advancing the understanding of nipocalimab and supporting more research that may help address persistent unmet needs for people living with systemic lupus erythematosus.”